-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1749 The “Walk through the Clinic Door” Effect: Differences in Survival and Toxicity Based on Site of CAR T Administration in a Default Outpatient CAR T Program

Program: Oral and Poster Abstracts
Session: 628. Aggressive Lymphomas: Cellular Therapies: Poster I
Hematology Disease Topics & Pathways:
Research, Lymphoid Leukemias, ALL, Epidemiology, Lymphomas, Clinical Research, Health outcomes research, B Cell lymphoma, Plasma Cell Disorders, Diseases, Lymphoid Malignancies, Adverse Events
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Bradley D. Hunter, MD, MPH, Daanish Hoda, Julie Asch, MD and Prashant Sharma, MD

LDS Hospital, Intermountain Health, Salt Lake City, UT

Introduction:

Due to the potential of long-term PFS, CAR T-cell therapy is frequently given to patients with suboptimal performance status (PS). Differences in outcomes regarding PS of 2 or greater have been demonstrated in real world analyses of CAR T outcomes. However, it is unknown if patients who require hospitalization at the time of CAR T-cell infusion due to non-CAR T comorbidities have differential outcomes compared to patients who would otherwise be able to “walk into clinic.” To date, many patients are infused with CAR T as inpatients due to monitoring needs, not necessarily due to medical status. The Intermountain Health CAR T-cell program’s default infusion setting is outpatient for all commercial CAR T-cell products, thus allowing for a more accurate evaluation of the association between true inpatient status and CAR T-cell therapy related outcomes.

Methods:

Patients were identified from scheduling and billing records. Patient’s oncology notes for CAR-T 30-day, 100-day and 1 year follow up visits were reviewed to evaluate setting of CAR-T infusion, treatment response and toxicity. Survival was determined by any death record within the IH EMR and the patient’s last known visit date. Two proportion pooled z-tests were calculated to compare OS rates between inpatient and outpatient groups.

Results:

There were 125 patients included in this analysis. 5 patients received CAR T for ALL, 98 patients received CAR T for B-cell lymphoma, and 22 patients received CAR T for multiple myeloma. 27/125 patients (22%) received CAR T-cell therapy in the inpatient setting, and 98/125 (78%) were infused at as outpatients. Overall survival (OS) was significantly inferior for patients who received CAR T-cell therapy as inpatients vs outpatients, with 30 -day OS of 81% vs 97% (p=0.02), 90- day OS of 56% vs 92% (p<0.01), and 1 year OS of 30% vs 77% (p<0.01). 1 year CR rates were 19% in inpatients vs 48% in outpatients. Among lymphoma patients, 7/21 (33%) of those who received inpatient CAR T were alive at 1 year, vs 59/77 (77%) of outpatients (p<0.01). For multiple myeloma patients, 1 year OS for those who received inpatient infusion was 25% (1/4 patients), vs 72% (13/18) for outpatients (p=0.02). Grade 3+ CRS in inpatients was 30% for inpatients vs 2% in outpatients (p,0.01). Grade 3+ ICANS was 26% in inpatients vs 10% in outpatients (p=0.04).

Conclusion:

Patients who require inpatient CAR T-cell administration due to performance status experienced significantly inferior OS and rates of CR at 1 year compared to patients who received CAR T-cell therapy in the outpatient setting. Rates of high-grade CRS and ICANS were significantly increased in patients who required inpatient CAR T administration. There appears to be a “walk through the clinic door” effect that may better capture CAR T-cell treatment risk for both outcomes and toxicity.

Disclosures: Hunter: Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Regeneron: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Kite: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Genentech: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; In8 Bio: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Genmab: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ADC Therapeutics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Speakers Bureau; AbbVie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Astellas: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Notable Labs: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Hoda: BMS: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ADC Therapeutics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Asch: Amgen: Consultancy, Honoraria; Jazz Pharmaceuticals: Honoraria, Speakers Bureau.

*signifies non-member of ASH